Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in October

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 421,900 shares, a drop of 28.9% from the October 15th total of 593,700 shares. Currently, 1.4% of the company’s shares are sold short. Based on an average daily trading volume, of 75,800 shares, the short-interest ratio is presently 5.6 days.

Wall Street Analysts Forecast Growth

ANIX has been the topic of a number of recent analyst reports. EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a “strong-buy” rating in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, September 17th.

Anixa Biosciences Price Performance

ANIX opened at $3.10 on Thursday. The business has a fifty day simple moving average of $3.27 and a 200 day simple moving average of $2.99. The company has a market capitalization of $99.76 million, a PE ratio of -7.95 and a beta of 0.84. Anixa Biosciences has a 1 year low of $2.14 and a 1 year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Equities analysts anticipate that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors have recently modified their holdings of the business. Tyler Stone Wealth Management increased its stake in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the period. International Assets Investment Management LLC increased its stake in shares of Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the period. Concorde Asset Management LLC acquired a new stake in shares of Anixa Biosciences in the second quarter valued at about $31,000. Nations Financial Group Inc. IA ADV increased its stake in shares of Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares during the period. Finally, Virtu Financial LLC boosted its position in shares of Anixa Biosciences by 47.2% during the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after purchasing an additional 5,183 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.